Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant
Bharat Biotech has updated the efficacy of Covaxin to 65.2% against the Delta variant in - Effectiveness Study on Delta Variant - Lancet Infectious Diseases, published on Nov 23 2021.
"Bharat Biotech commends the investigators from the All India Institute of Medical Sciences (AIIMS) on the BBV152 study published in Lancet Infectious Diseases. These results provide evidence for effectiveness for Covaxin in real life settings," Bharat Biotech said. Read more
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Subscribe To Insights
Key stories on business-standard.com are available to premium subscribers only.Already a BS Premium subscriber? Log in NOW
Or